Please login to the form below

Not currently logged in
Email:
Password:

Orphan drug firm Sobi opens new European base

Company'sBrussels office will also house its Benelux operations

Swedish Orphan Biovitrum Sobi

Sobi (Swedish Orphan Biovitrum) has opened doors on its new European and Benelux office in Brussels.

The company said the move was a reflection of its expanding international presence and would act as an operational hub for its business.

Hege Hellstrom, president EMENAR at Sobi, said: "Brussels provides an ideal location for our European operations. Being a company dedicated to rare diseases, Brussels is of vital importance to Sobi from a business, regulatory, policy and stakeholder interaction perspective.

“The Belgian authorities have also consistently been thought leaders in collaborative, cross-border approaches to access and availability of rare disease therapies for patients."

The rare disease-focused specialty pharmaceutical company has more than 600 employees who concentrate primarily on its work in haemophilia, inflammation and genetic diseases.

In July the European Commission approved an oral suspension formulation of Orfadin (nitisinone), which treats the rare - and potentially fatal - genetic disease Hereditary Tyrosinaemia type-1 (HT-1).

More recently the FDA this week began its review of the oral suspension formulation of Orfadin, and Sobi said a formal decision on the product from the US regulator is expected during the second quarter 2016.

Article by
Dominic Tyer

11th September 2015

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics